ProfileGDS5678 / 1428076_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 96% 96% 95% 95% 95% 94% 95% 96% 95% 95% 95% 95% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.4977995
GSM967853U87-EV human glioblastoma xenograft - Control 28.9850896
GSM967854U87-EV human glioblastoma xenograft - Control 38.8792696
GSM967855U87-EV human glioblastoma xenograft - Control 48.7555995
GSM967856U87-EV human glioblastoma xenograft - Control 58.6872495
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3350795
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0266794
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5337295
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.8177496
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.625895
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.2652895
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.6571495
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.5180895
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.7092396